|
Video: What is a Stock Split?
|
|
Selecta Biosciences is a clinical-stage biopharmaceutical company. Co.'s ImmTOR® platform encapsulates rapamycin, also known as sirolimus, a Food and Drug Administration approved immunomodulator, in biodegradable nanoparticles ImmTOR is designed to induce antigen-specific immune tolerance. By combining ImmTOR with antigens of interest, Co.'s immune tolerance platform restores self-tolerance to auto-antigens in autoimmune diseases, amplify the ability of biologics (including gene therapies) and mitigate the formation of anti-drug antibodies against biologic drugs. According to our RNAC split history records, Cartesian Therapeutics has had 1 split. | |
|
Cartesian Therapeutics (RNAC) has 1 split in our RNAC split history database. The split for RNAC took place on April 05, 2024. This was a 1 for 30 reverse split, meaning for each 30 shares of RNAC owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 33.3333333333333 share position following the split.
When a company such as Cartesian Therapeutics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the RNAC split history from start to finish, an original position size of 1000 shares would have turned into 33.3333333333333 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Cartesian Therapeutics shares, starting with a $10,000 purchase of RNAC, presented on a split-history-adjusted basis factoring in the complete RNAC split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
06/23/2016 |
|
End date: |
04/26/2024 |
|
Start price/share: |
$420.90 |
|
End price/share: |
$21.03 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-95.00% |
|
Average Annual Total Return: |
-31.74% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$499.77 |
|
Years: |
7.85 |
|
|
|
Date |
Ratio |
04/05/2024 | 1 for 30 |
|
|